Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in healthy volunteers

Pharmacological Research

Volumn 49, Issue 5, 2004, Pages 493-499

  Calabresi, Laura ^a   Pazzucconi, Franco ^a   Ferrara, Stefano ^a   Di Paolo, Antonello ^b   Del Tacca, Mario ^b   Sirtori, Cesare ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Clarithromycin; Drug interactions; Omeprazole; Pantoprazole; Proton pump inhibitors

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; ENZYME METABOLISM; HELICOBACTER PYLORI; HUMAN; MALE; METABOLISM; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CLARITHROMYCIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GENOTYPE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES;

EID: 1442357998     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.10.010     Document Type: Article

References (37)

1. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P4503A4 inhibition. Clin. Pharmacokinet. 38:2000;41-57.
2. Omar M.A., Wilson J.P., Cox T.S. Rhabdomyolysis and HMG-Co reductase inhibitors. Ann. Pharmacol. Ther. 35:2001;1096-1107.
3. Schlienger R.G., Haefeli W.E., Jick H., Meier C.R. Risk of cataract in patients treated with statins. Arch. Int. Med. 161:2001;2021-2026.
4. Sung J.J.K., Chung S.C.S., Ling T.K.W.et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N. Engl. J. Med. 332:1995;139-145.
5. Hunt R.H. Eradication of Helicobacter pylori infection. Am. J. Med. 100:1996;42S-51S.
6. de Morais S.M.F., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46:1994;594-598.
7. Furuta T., Oshashi K., Kosuge K., Zhao X.-J.et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65:1999;552-561.
8. Tanigawara Y., Aoyama N., Kita T.et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 66:1999;528-534.
9. Andersson T., Miners J.O., Veronese M.E., Birkett D.J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 37:1994;597-604.
10. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13(Suppl. 3):1999;27-36.
11. Furuta T., Oshashi K., Kobayashi K.et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin. Pharmacol. Ther. 66:1999;265-274.
12. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chem 1995;39:2078-83.
13. Bliesath H., Huber R., Steinijans V.W., Koch H.J., Kunz K., Wurst W. Pantoprazole does not interact with nifedipine in man under steady-state conditions. Int. J. Clin. Pharmacol. Ther. 34:1996;51-55.
14. Tanaka M., Ohkubo T., Otani K.et al. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 69:2001;108-113.
15. Kobayashi K., Chiba K., Sohn D.R., Kato Y., Ishizaki T. Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. J. Chromatogr. 579:1992;299-305.
16. Sastre Torano J., Guchelaar H.J. Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. J. Chromatogr. B. 720:1998;89-97.
17. Rodvold K.A. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:1999;385-398.
18. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84:1999;413-428.
19. Davidson M.H. Does differing metabolism by cytochrome p450 have clinical importance? Curr. Atheroscl. Rep. 2:2000;14-19.
20. Karam W.G., Goldstein J.A., Lasker J.M., Ghanayem B.I. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab. Dispos. 10:1996;1081-1087.
21. Zhou Q., Yamamoto I., Fukuda T., Ohno M., Sumida A., Azuma J. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur. J. Clin. Pharmacol. 55:1999;43-47.
22. Rost K.L., Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology. 23:1996;1491-1497.
23. Kees F., Holstege A., Ittner K.P., Zimmermann M., Lock G., Scholmeric J.et al. Pharmacokinetic interaction between proton pump inhibitor and roxithromycin in volunteers. Aliment Pharmacol. Ther. 14:2000;407-412.
24. Kang B.C., Yang C.Q., Cho H.K., Ok S., Shin W.G. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm. Drug Dispos. 23:2002;77-81.
25. Bailey D.G., Malcolm J., Arnold O., Spence J.D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46:1998;101-110.
26. Tassaneeyakul W., Tassaneeyakul W., Vannaprasaht S., Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br. J. Clin. Pharmacol. 49:2000;139-144.
27. Mouly S., Paine M.F. Effect of grapefruit juice on the disposition of omeprazole. Br. J. Clin. Pharmacol. 52:2001;213-217.
28. Ushiama H., Echizen H., Nachi S., Ohnishi A. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6β-hydroxycortisol. Clin. Pharmacol. Ther. 72:2002;33-43.
29. Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin. Pharmacokinet. 38:2000;243-270.
30. Kromer S., Postius R., Riedal W.A.et al. Pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J. Pharmacol. Exp. Ther. 129:1990;150-155.
31. Shin J.M., Besancon M., Prinz C., Simon A., Sachs G. Continuing development of acid pump inhibitors: site of action of pantoprazole. Aliment Pharmacol. Ther. 8(S1):1994;11-23.
32. Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 23:1992;106-131.
33. Pedrazzoli J. Jr., Calafatti S.A., Ortiz R.A.et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand. J. Gastroenterol. 36:2001;1248-1253.
34. Calafatti S.A., Ortiz R.A.M., Deguer M., Martinez M., Pedrazzoli J. Jr. Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. Br. J. Clin. Pharmacol. 52:2001;205-209.
35. Holtmann G, Bytzer P, Metz, Loeefler V, Blum AL. A randomized, double blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479-85.
36. Lutz M., Schwab M., Griese E.U.et al. Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism. Pharmacogenetics. 12:2002;73-75.
37. Tucci A., Corinaldesi R., Stanghellini V.et al. One-day therapy for treatment of Helicobacter pylori infection. Dig. Dis. Sci. 38:1993;1670-1673.